ascopubs.org

Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center

A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the ...
ascopubs.org

Using Artificial Intelligence to Support Informed Decision-Making on BRAF Mutation Testing

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
Reuters

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...
Targeted Oncology

Progress and Gaps in Lung Cancer Biomarker Testing at Community Centers

Comprehensive biomarker testing is crucial for NSCLC treatment, yet disparities exist between academic and community settings ...
Nasdaq

FDA OKs Guardant360 CDx As Companion Test For BRAF V600E Metastatic Colorectal Cancer

(RTTNews) - Guardant Health, Inc. (GH) said Thursday that the U.S. Food and Drug Administration has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with BRAF ...
Reuters

Biocartis Group announces CE-marking of its Idylla NRAS-BRAF mutation test

Dec 15 (Reuters) - Biocartis Group Nv : * Biocartis Group: CE-marking Idylla NRAS-BRAF mutation test completes offering of metastatic colorectal cancer tests for clinical use on Idylla platform Source ...